Global Health News - Week ending 11 October 2026

WHO launches global guidelines on obesity in children and adolescents

The World Health Organization (WHO) launched two new guidelines on the integrated management of obesity in children and adolescents on 7 October 2026. In 2024, an estimated 400 million children and adolescents aged 5 to 19 were overweight, including 170 million living with obesity, and prevalence has quadrupled since 1990, rising from 2% to 8% over the past 35 years. The guidelines strongly recommend structured changes to diet, behaviour and physical activity as the foundation of care, and also set out advice on pharmacological treatment, bariatric surgery and weight loss devices. Management is framed as going beyond weight loss alone, covering overall health and wellbeing.

Why it matters: Obesity care is moving from single interventions to structured, long term management, and pharmacists will increasingly advise on medicines, devices and lifestyle support within multidisciplinary care.

Source: World Health Organization, 7 October 2026

World Top Stories

WHO publishes global roadmap for hypertensive disorders of pregnancy

WHO published a global roadmap on 7 October 2026 to accelerate action on hypertensive disorders of pregnancy, including pre-eclampsia, which account for about 16% of maternal deaths worldwide, around 42,000 deaths, and more than 500,000 stillbirths and newborn deaths. The 74 page roadmap sets out five areas of work: research and innovation, norms and standards, access to health products, implementation, and advocacy and accountability. Its stated aim is to speed progress towards ending preventable maternal and newborn mortality and morbidity and stillbirth, contributing to Sustainable Development Goal targets 3.1 and 3.2. The burden falls unevenly, with women and newborns in low and middle income countries disproportionately affected, and many countries still lack reliable blood pressure measurement, testing and essential medicines. The roadmap also addresses the innovation gap for medicines to prevent or treat pre-eclampsia.

Why it matters: Hypertensive disorders of pregnancy are a leading, largely preventable cause of maternal death, and the roadmap shows students how guidelines, product access and implementation must move together.

Source: World Health Organization, 7 October 2026

WHO publishes guide to community based mental health care

WHO published a guide on 9 October 2026 to support the transition from long stay psychiatric hospitals to community based mental health and social care for adults. Aimed at psychiatric hospital leaders and decision makers, the guide is organised in three phases, plan, prepare and provide, and identifies three areas where hospitals can influence the shift: reducing admissions and lengths of stay, transforming care within hospitals, and increasing supported discharge, continuity of care and community participation. The publication frames deinstitutionalisation as a managed process rather than simply closing beds, with community services built up alongside changes inside hospitals.

Why it matters: The move from institutional to community care is one of the biggest structural shifts in mental health services, and pharmacists play a central role in medicines continuity when patients move between hospital and community settings.

Source: World Health Organization, 9 October 2026

WHO seeks clarity after suspected pneumonic plague case reported in Irkutsk

WHO said it was seeking further information after media reports on 2 October 2026 of a suspected case of pneumonic plague in a laboratory worker at the Irkutsk Antiplague Research Institute in the Russian Federation, who died after hospitalisation with severe pneumonia. Initial reports suggested the illness followed accidental laboratory exposure. WHO asked the Russian Federation for more information on 3 October under the International Health Regulations, and Russia responded that no case of plague had recently been reported in Irkutsk oblast and that about 200 contacts had been placed in quarantine. WHO requested further details on laboratory tests, what prompted the measures, the health status of contacts, and verification of media reports of a second employee with pneumonia of undetermined cause, offered technical support on plague and laboratory biosafety and biosecurity, and said it could not yet conduct a full risk assessment. Plague was not confirmed in the information available to WHO.

Why it matters: The episode is a live lesson in outbreak verification, the International Health Regulations, and why suspected cases must not be reported as confirmed, especially for a high consequence pathogen.

Source: World Health Organization, 7 October 2026

Bundibugyo virus disease in the Democratic Republic of the Congo passes 8,600 confirmed cases

Confirmed cases of Bundibugyo virus disease in the Democratic Republic of the Congo had reached 8,665, with 4,178 confirmed deaths, WHO reported on 7 October 2026. Transmission was showing clear signs of slowing in some areas while continuing to grow in others, including new hotspots close to the border with South Sudan. Contact tracing had improved, with around 2,000 alerts reported every day and about 5 million people reached through community engagement. Clinical trials of therapeutics were progressing with more than 600 people enrolled, and a vaccine trial was expected to start later in October 2026. WHO noted that the majority of deaths were still happening in the community rather than in treatment centres, a pattern that limits the impact of available care.

Why it matters: This is the largest Bundibugyo outbreak on record, and it shows students how case finding, community engagement, therapeutics trials and vaccine trials run in parallel during a major filovirus outbreak.

Source: World Health Organization, 7 October 2026

Oral deucrictibant brings faster relief in hereditary angioedema attacks, phase 3 trial finds

A phase 3, double blind, 2 by 2 crossover trial published in The Lancet on 8 October 2026 tested a single oral capsule of deucrictibant against placebo for acute hereditary angioedema attacks. The trial enrolled adolescents aged 12 to under 18 and adults aged 18 to 75 at 59 sites across 24 countries on six continents, randomised 134 participants, and treated 201 attacks in 113 participants. In the primary analysis of 88 participants with paired treated attacks, median time to onset of symptom relief was 1.28 hours with deucrictibant compared with more than 12 hours with placebo, a statistically significant difference. Fatigue was the only adverse event reported more than once within three days of treatment, no treatment related adverse events were assessed as severe or serious, and none led to discontinuation.

Why it matters: Hereditary angioedema attacks are usually treated with injections, so an effective oral on demand option would change how patients manage attacks, and the crossover design is a good example of efficient trial design in a rare disease.

Source: The Lancet, 8 October 2026

Antibody drug combination shows high complete response in unresectable bladder cancer

A phase 2, open label, single arm, non-randomised trial published in JAMA Oncology on 8 October 2026 tested disitamab vedotin, an anti-ERBB2 antibody drug conjugate, plus tislelizumab, an immune checkpoint inhibitor, in adults with transurethrally unresectable, ERBB2 positive, very high risk non-muscle-invasive bladder cancer who were ineligible for or declined radical cystectomy. Among 26 patients evaluable for efficacy, 19 achieved a complete response of high risk disease, a rate of 73.1%, meeting the prespecified 70% target, and among all 28 treated patients the rate was 67.9%. Among responders, the estimated sustained response rate at 24 months was 83.5%, and no patient progressed to muscle invasive or metastatic disease during a median follow up of 29.4 months. Treatment related adverse events occurred in 25 patients, most commonly paraesthesia, alopecia and pruritus, with grade 3 to 4 events in four patients and discontinuation in two.

Why it matters: For patients who cannot have or decline bladder removal, a bladder sparing drug combination with durable responses is a major development, and the small single arm design shows why randomised confirmation is still needed.

Source: JAMA Oncology, 8 October 2026

BMJ opinion urges caution on multicancer blood test after NHS trial misses primary endpoint

A BMJ opinion published on 8 October 2026 argued that the NHS should not follow the path taken in the United States on the Galleri multicancer early detection blood test, after the NHS-Galleri randomised trial failed to meet its primary endpoint. In the trial, run in partnership with the NHS, half of 142,250 participants were randomised to receive the Galleri test and half were not, with the aim of achieving a statistically significant reduction in the incidence of 12 prespecified cancer types at stage 3 or 4. After three years of annual blood tests there was no significant difference in incidence between the groups, although 52% of the 1,801 participants with a positive test over three rounds had a cancer diagnosis, and the test identified the tissue of origin accurately 87% of the time. Mortality data were not presented and are expected two years after the primary endpoint. In the United States, an FDA advisory panel voted six to four that there was reasonable assurance the test is effective, a non-binding recommendation, and the opinion warns that lobbying and financial interests must not weaken stringent, conflict free decision making.

Why it matters: Screening tests need proof that they reduce deaths, not just that they find cancers, and this case teaches students to separate test accuracy, trial endpoints and regulatory decisions.

Source: The BMJ, 8 October 2026

South Asia

Only 3 stories met the bar this week

India's eSanjeevani telemedicine service crosses 500 million consultations

India's National Telemedicine Service, eSanjeevani, crossed 50 crore teleconsultations, reaching a cumulative 50,00,92,730 consultations across all 36 States and Union Territories, the Ministry of Health and Family Welfare announced on 6 October 2026, with the landmark itself crossed on 15 September 2026. The service is described as the world's largest telemedicine implementation in primary healthcare, running through more than 1.42 lakh Ayushman Arogya Mandir spokes, 19,473 medical hubs and 901 online outpatient departments, with 2,41,923 registered healthcare providers and availability in 15 languages. Around 2.5 to 3 lakh consultations take place daily, and the highest single day utilisation reached 6,30,315. Women account for 57.14% of use, and 40.15% of consultations are by citizens aged 46 and above, including 16.25% by senior citizens aged 60 and above. An AI powered clinical decision support system is integrated into the platform, which is also linked to the Emergency Response Support System (112), and specialist outpatient consultations have been rolled out at AIIMS Jodhpur, AIIMS Jammu and AIIMS Patna.

Why it matters: Telemedicine at this scale changes how primary care, triage and follow up work, and pharmacists need to understand remote consultation flows, digital records and referral pathways.

Source: Press Information Bureau, Government of India, 6 October 2026

India launches youth led JOSH Teams to push towards tuberculosis elimination

The Union Ministry of Health and Family Welfare, together with the Ministry of Youth Affairs and Sports and the Ministry of Defence, was to launch JOSH (Joint Squad for Health) Teams on 8 October 2026 at Bharat Mandapam, New Delhi, under the TB Mukt Bharat campaign. In the first phase, teams will work across 55 districts in 11 States, combining Class-I Officers, MY Bharat Volunteers and NCC Cadets for youth led community mobilisation. Their messages cover tuberculosis symptoms, prevention, timely diagnosis and treatment completion, and tackling myths, misconceptions and stigma. The launch event was also to feature an achievement video, new information, education and communication materials, and Khushi Avatar, an AI powered chatbot. In 2025, 67,933 Panchayats across 697 districts were recognised as TB Mukt.

Why it matters: Tuberculosis elimination depends as much on community mobilisation, stigma reduction and treatment completion as on medicines, and this is a large scale example of youth volunteers supporting a national programme.

Source: Press Information Bureau, Government of India, 7 October 2026

Tele-MANAS mental health helpline passes 47 lakh calls ahead of World Mental Health Day

The Ministry of Health and Family Welfare announced on 9 October 2026 that it would observe World Mental Health Day on 10 October 2026 under the theme "Lived experiences heard: real voices, real change", and set out the reach of the Tele-MANAS national toll free helpline, 14416, which provides free, confidential, round the clock counselling. Launched on 10 October 2022, the helpline had received 47,75,644 calls, with 53 operational cells across all 36 States and Union Territories as of October 2026. Of 13,35,275 recorded caller profiles, women account for 43.78% and men for 54.18%, and individuals aged 18 to 45 account for 73.2%. Alongside the helpline, the MANN Jaagriti community awareness initiative is running, the District Mental Health Programme has been sanctioned for 767 districts, and mental health services have been integrated into over 1.83 lakh Ayushman Arogya Mandirs.

Why it matters: A national, free, round the clock counselling helpline shows how mental health support is being scaled beyond hospitals, and students should understand referral routes and the limits of telephone based support.

Source: Press Information Bureau, Government of India, 9 October 2026

Europe

Only 2 stories met the bar this week

EU clinical trial advice pilot becomes permanent from January 2027

The European Medicines Agency announced on 8 October 2026 that the Accelerating Clinical Trials in the EU (ACT EU) advice pilot, which helps sponsors prepare clinical trial applications, will become a permanent initiative from January 2027. The initiative aims to raise the quality of applications and make assessment more efficient by strengthening cooperation across the European medicines regulatory network. Coordinated by the Heads of Medicines Agencies through its Clinical Trials Coordination Group, the advice procedure gives sponsors technical and regulatory support before they submit an application through the Clinical Trials Information System, with consolidated feedback from the Member States concerned on key pre-submission topics. Before the pilot, sponsors could only receive such support at national level from the Member State responsible for evaluating their application. ACT EU will continue to manage applications already submitted under the pilot until the end of 2026, a final report on around 30 pilot applications will be published before the end of 2026, and updated guidance and templates will appear on the coordination group website in January 2027.

Why it matters: Better pre-submission advice means better designed trials and fewer avoidable protocol problems, which matters for anyone who will run, review or work on clinical trials in Europe.

Source: European Medicines Agency, 8 October 2026

EMA opens consultation on equivalence rules for nasal medicines

The European Medicines Agency opened a public consultation on 8 October 2026 on a draft guideline setting out the data needed to demonstrate therapeutic equivalence between nasal medicinal products containing the same active substance or substances. The guideline complements the existing guideline on the pharmaceutical quality of inhalation and nasal products and covers both locally acting products, such as xylometazoline, fluticasone and azelastine, and systemically acting products, such as naloxone, desmopressin, fentanyl, ketamine and zolmitriptan. For locally acting products it proposes a stepwise approach, starting with in vitro comparison and moving to pharmacokinetic studies where in vitro similarity cannot be shown, while pharmacodynamic or clinical endpoints are generally not recommended because they are seldom sensitive enough. For systemically acting products, bioequivalence studies are generally required, although a waiver based on in vitro data is possible for solutions meeting all criteria. The consultation runs until 28 February 2027.

Why it matters: Nasal sprays are widely used and hard to compare, so clear equivalence rules directly affect generic development, product quality and what reaches pharmacy shelves.

Source: European Medicines Agency, 8 October 2026

North America

Only 3 stories met the bar this week

FDA approves Hovilpri for herpes simplex lesions that do not respond to standard antivirals

The US Food and Drug Administration approved Hovilpri (pritelivir) on 9 October 2026 for adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection that does not respond to acyclovir, valacyclovir or famciclovir. Such lesions occur on the skin or mucosal surfaces, including the lips, nostrils, eyes and genitals. Efficacy was assessed in PRIOH-1 Phase 3 Trial Part C, a randomised, open label, comparator controlled superiority trial in 101 immunocompromised adults, in which all lesions had healed by 28 days in 63% of those receiving Hovilpri compared with 34% of those receiving investigator chosen alternatives. Headache was the most common adverse reaction, and the approval was granted under priority review.

Why it matters: Drug resistant herpes simplex infection in immunocompromised patients has had few options, so a new treatment with a clear trial result is directly relevant to antiviral and immunocompromised care.

Source: US Food and Drug Administration, 9 October 2026

Two lots of anaesthetic Brevital Sodium recalled over particulate matter

Par Health voluntarily recalled two lots of Brevital Sodium 500 mg per vial (methohexital sodium for injection) to the hospital level in the United States, the Food and Drug Administration announced on 9 October 2026, after particulate matter identified as cellulose was found in the product. The affected lots, 86930 with expiry in February 2028 and 88623 with expiry in April 2028, were distributed nationwide to wholesalers between 8 July 2025 and 11 May 2026. The agency states there is a reasonable probability of life-threatening consequences, including pulmonary emboli, vessel occlusions, and inflammation of vein walls with clotting, and no reports of adverse events related to the recall had been received to date. Brevital Sodium is an ultra short acting barbiturate anaesthetic used for induction of anaesthesia and procedural sedation.

Why it matters: Particulate contamination in an injectable anaesthetic is a serious quality failure, and recalls like this show why batch checking, quarantine and hospital level recall procedures are core pharmacy work.

Source: US Food and Drug Administration, 9 October 2026

Frequent mental distress among young US adults remains far above 2012 levels, CDC finds

A US Centers for Disease Control and Prevention analysis published on 8 October 2026 found that frequent mental distress among adults aged 18 to 29 rose from 12.7% in 2012 to 21.3% in 2024, after peaking at 23.7% in 2022 and falling in both 2023 and 2024. Frequent mental distress was defined as reporting 14 or more mentally unhealthy days in the past 30 days, and the analysis drew on 424,558 respondents to the Behavioral Risk Factor Surveillance System between 2012 and 2024. Physical inactivity, defined as no physical activity outside work in the past month, rose from 15.9% in 2012 to 16.8% in 2024, after falling from 18.4% in 2023. In 2024, frequent mental distress was highest in Oregon (30.2%), Nevada (27.9%) and Louisiana (27.1%), and 47 of 53 jurisdictions saw a statistically significant increase in distress between 2012 and 2024. The authors note the data are self reported and cross sectional, so they describe trends but cannot show what caused them.

Why it matters: Young adults report the highest prevalence of mental health conditions of any adult age group, and the link with physical activity makes this essential context for community pharmacy, health promotion and early support.

Source: US Centers for Disease Control and Prevention, 8 October 2026

Africa

Only 1 story met the bar this week

Kenya reports first imported Bundibugyo virus disease case

Kenya reported its first imported case of Bundibugyo virus disease, a form of Ebola disease, in a Kenyan citizen who fell ill in the Democratic Republic of the Congo, was treated at several facilities there, and then travelled to Nairobi via Kampala, WHO reported on 7 October 2026. Immediately on arrival in Nairobi, the patient was taken to hospital and isolated, Ebola was confirmed, and he received care but died on the Monday of that week. Kenyan authorities were monitoring 55 contacts, including passengers and crew on the flight from Kampala to Nairobi. WHO commended Kenya's prompt action and timely reporting under the International Health Regulations and advised against blanket travel or trade restrictions.

Why it matters: Imported cases test every part of a health system, from airport detection and isolation to contact tracing and risk communication, and Kenya's rapid response is a model of International Health Regulations working as intended.

Source: World Health Organization, 7 October 2026

← Newer: Week ending 18 October 2026  ·  Older: Week ending 4 October 2026 →  ·  All Global Health News

Every story on this page was verified on its original source page. Coverage is pharma, medical, healthcare and community health only; no politics or finance.